Study wrapper · #126
Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.
Editor's note
A systematic review (PROSPERO-registered) of GLP-1 agonists in NAFLD/MASLD and MASH, synthesizing 12 studies narratively because of heterogeneity in populations and outcomes. Its conclusions are appropriately graded. The most consistent finding across semaglutide, liraglutide, dulaglutide, and beinaglutide was reduction in hepatic fat. Liver-enzyme improvements (notably ALT) were less consistent and, as the authors note, should be read as supportive rather than definitive of histological change. Histological benefit was strongest for steatohepatitis resolution in non-cirrhotic MASH; fibrosis results were mixed, with the greatest benefit in intermediate F2-F3 disease and little in established cirrhosis. Tolerability was generally acceptable with gastrointestinal effects most common. This aligns with the broader picture, GLP-1 agonists reliably reduce liver fat and can resolve steatohepatitis in earlier-stage disease, but their effect on advanced fibrosis and hard long-term outcomes remains unproven. A narrative synthesis cannot quantify pooled effect, and the studies are heterogeneous. Weight as moderate, encouraging evidence with clear boundaries at advanced disease.
Plain-language abstract
This is a systematic review of how GLP-1 medications affect fatty liver disease, now often called MASLD, and its more severe form with inflammation, MASH. The authors searched major medical databases and included 12 studies. Because the studies differed too much to combine numerically, they summarized the findings in words. The most consistent result across several GLP-1 drugs, including semaglutide and liraglutide, was a reduction in the amount of fat in the liver. Improvements in liver enzyme blood tests (a rough sign of liver inflammation) were less consistent and are best seen as supportive rather than solid proof of deeper improvement. When liver tissue was examined, the clearest benefit was resolving the inflammatory form of the disease in patients who did not yet have cirrhosis. Effects on scarring (fibrosis) were mixed, strongest in moderate-stage disease and limited once cirrhosis was established. The drugs were generally well tolerated, with stomach and gut symptoms the most common side effect. The authors conclude the results are promising for earlier-stage liver disease but that longer, larger studies are needed for advanced scarring and long-term outcomes.